AAO 2019 To Feature Multiple Presentations by Leading Experts on Allegro’s Dry Age-Related Macular Degeneration and Dry Eye Disease Assets Download the PDF SAN JUAN CAPISTRANO, CA — October 8, 2019 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel therapies that regulate select integrin functions for the treatment of […]
Results of Allegro’s Ex-U.S. Proof-of-Concept Trial with Integrin Regulator ALG-1007 for Dry Eye Disease Will Be Presented at the 37th Congress of the ESCRS Download the PDF SAN JUAN CAPISTRANO, CA — September 3, 2019 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel therapies that regulate select integrin […]
Risuteganib Met Visual Acuity Primary Endpoint with Statistical Significance in U.S. Phase 2 Trial Download the PDF SAN JUAN CAPISTRANO, CA — July 24, 2019 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel therapies that regulate select integrin functions for the treatment of ocular diseases, today announced that […]
— U.S. Phase 2 Trial Met Primary Endpoint with Statistical Significance — 48% of Patients in the Risuteganib Arm Gained ≥ 8 Letters of Vision from Baseline Download the PDF SAN JUAN CAPISTRANO, CA — June 4, 2019 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies […]
Results of the Trial Suggest that ALG-1007 is Well-Tolerated and Demonstrates a Dose Response with Improvement as Early as Two Weeks Download the PDF SAN JUAN CAPISTRANO, CA — May 14, 2019 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, […]
ALG-1007 Marks Allegro’s Second Exploratory Anti-Integrin Drug Candidate—Now, for the Potential Treatment of Dry Eye Disease Download the PDF SAN JUAN CAPISTRANO, CA — April 30, 2019 — Following last week’s news that the company is expanding its pipeline into dry eye and has created a new Cornea Scientific Advisory Board (Cornea SAB), Allegro Ophthalmics, […]
Richard L. Lindstrom, M.D., Edward J. Holland, M.D., and Eric D. Donnenfeld, M.D., Join Allegro’s Newly-Formed Cornea Scientific Advisory Board Download the PDF SAN JUAN CAPISTRANO, CA — April 25, 2019 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today […]
New Members Bring Extensive Commercial and Financial Expertise from Private and Public Companies Download the PDF SAN JUAN CAPISTRANO, CA — April 9, 2019 —Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced that two new independent members—Marc Carlson and […]
Hampar Karageozian, Co-Founder and Former CEO, Named Executive Chairman Vicken Karageozian, MD, Co-Founder and Former President and CMO, Named President and CEO Download the PDF SAN JUAN CAPISTRANO, CA — August 21, 2018 —Allegro Ophthalmics, LLC, a late stage ophthalmic biopharmaceutical company focused on the development of therapies to treat retinal diseases, today announced that […]
Risuteganib regulates mitochondrial dysfunction and downregulates oxidative stress response to restore retinal homeostasis Research suggests that risuteganib interferes with mitochondrial dysfunction that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Risuteganib reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, […]
